4 stories this morning, for surgeons and the people who support them.
- Zimmer Biomet splits the Americas job three ways and staffs a dedicated robotics salesforce ahead of Monogram — Effective October 1, Gary Campbell becomes President, Americas; Brian Hatcher takes Recon, S.E.T., CMFT, Neuro and Biosurgery; Bradley Kessler takes a newly created President, Americas - Robotics, Technology and Data, all reporting to CEO Ivan Tornos. Kevin Thornal, who held Global Businesses and the Americas as one role, departs at the end of September. Kessler's mandate is to expand a specialized robotics salesforce ahead of the Monogram robot's early-2027 launch. Source
- Shoulder Innovations and Catalyst OrthoScience settle their two-and-a-half-year patent fight — The two shoulder arthroplasty companies settled all outstanding patent litigation on confidential terms. Shoulder Innovations sued in the District of Delaware in February 2024 over Catalyst's reverse shoulder systems; Catalyst counterclaimed in March 2024. Shoulder Innovations has been public on the NYSE since July 2025; Catalyst is private and has passed 10,000 total shoulder procedures across more than 300 US centers. Source
- Bioretec clears FDA 510(k) for the ActivaScrew Cannulated COM, a headless bioabsorbable compression screw — Cleared for fixation of bone and osteochondral fractures, osteotomies, arthrodeses and bone grafts in the hand, non-diaphyseal arm and forearm, foot and non-diaphyseal ankle in skeletally mature adults. It is built on the same PLGA material and process as the rest of the Activa family, which has sold more than half a million implants, rather than Bioretec's RemeOs magnesium line. Source
- MHRA accepts Biosplice's lorecivivint filing for knee osteoarthritis and starts its assessment — The UK regulator found the application complete and valid, starting the formal review timetable. Lorecivivint is an intra-articular small-molecule CLK/DYRK1A kinase inhibitor dosed once or twice a year. Biosplice submitted its FDA NDA on January 6, 2026 and says an EMA submission follows later this month. The program's Phase 3 OA-07 data included medial joint space width on imaging over multiple years, supporting a disease-modifying claim. Source
Contribute to the Brief
Faculty can send the show a note — a reaction to a paper, a correction, a read on a rule change — either written, which we shape for broadcast and read in the show's voice, or as a voice note under three minutes, which airs in your own voice. Send one from Studio.
Not on doc social yet? Contribute a lecture or join the network — doc social is a clinical education platform for clinicians, and this show is one part of it.
Narration is synthesized. Reporting and editorial judgement are ours, and every story above links to its source.